New Guidelines for Epilepsy Drug Development Released by EMA
⚠️ Infant dosing/safety: medication and diet decisions for infants require individualized medical guidance.
Source: Epilepsia
Summary
Researchers studied the changes in clinical guidelines for developing epilepsy medications set by the European Medicines Agency (EMA) between 2010 and 2025. They compared the 2025 guidelines with those from 2010 to see how recommendations for testing new treatments have evolved. This analysis involved looking at how terms and study designs have changed, especially in relation to different types of epilepsy and the needs of patients.
The key findings show that the new guidelines have updated terminology, replacing "antiepileptic drug" with "antiseizure medication." There is now more focus on outcomes that matter to patients, such as quality of life and functional improvements, rather than just seizure control. The guidelines also allow for new study designs, including using data from trials with additional treatments to support the use of a single treatment in some cases. Additionally, there is more guidance on how to study epilepsy treatments in children and rare forms of epilepsy.
These updates are important because they reflect a growing understanding of epilepsy and the need for better treatments, especially for children and those with rare conditions. However, the guidelines also have limitations, as they may not cover every situation or type of epilepsy. The changes were made with input from various experts, which helps ensure that the guidelines are relevant and useful for developing new medications.
Free: Seizure First Aid Quick Guide (PDF)
Plus one plain-language weekly digest of new epilepsy research.
Unsubscribe anytime. No medical advice.
